Northland Capmk Has Strong Forecast for TLSI FY2026 Earnings

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Analysts at Northland Capmk upped their FY2026 EPS estimates for TriSalus Life Sciences in a research note issued on Tuesday, November 26th. Northland Capmk analyst C. Byrnes now expects that the company will post earnings of ($0.60) per share for the year, up from their previous estimate of ($0.75). Northland Capmk has a “Strong-Buy” rating on the stock. The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($1.55) per share.

A number of other equities analysts have also recently commented on the company. Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Oppenheimer began coverage on TriSalus Life Sciences in a research report on Monday, September 16th. They set an “outperform” rating and a $10.00 price objective on the stock. Canaccord Genuity Group cut their price objective on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Roth Mkm began coverage on shares of TriSalus Life Sciences in a research note on Monday, November 11th. They set a “buy” rating and a $11.00 target price on the stock. Finally, Northland Securities began coverage on shares of TriSalus Life Sciences in a research report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price target for the company. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, TriSalus Life Sciences currently has a consensus rating of “Buy” and an average price target of $12.08.

TriSalus Life Sciences Price Performance

Shares of TriSalus Life Sciences stock opened at $4.56 on Thursday. TriSalus Life Sciences has a 1-year low of $3.61 and a 1-year high of $10.42. The company’s fifty day simple moving average is $4.23 and its 200-day simple moving average is $5.43. The stock has a market capitalization of $139.05 million, a PE ratio of -1.83 and a beta of 0.49.

Insider Buying and Selling

In related news, CEO Mary T. Szela bought 7,520 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was bought at an average cost of $5.20 per share, with a total value of $39,104.00. Following the completion of the purchase, the chief executive officer now owns 377,382 shares of the company’s stock, valued at approximately $1,962,386.40. The trade was a 2.03 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders have acquired 19,560 shares of company stock valued at $95,190. Corporate insiders own 32.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in TLSI. Highbridge Capital Management LLC bought a new position in TriSalus Life Sciences during the second quarter valued at approximately $1,184,000. Wolverine Asset Management LLC bought a new position in shares of TriSalus Life Sciences during the 2nd quarter valued at approximately $240,000. Duquesne Family Office LLC grew its holdings in shares of TriSalus Life Sciences by 35.1% in the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after purchasing an additional 110,966 shares in the last quarter. Geode Capital Management LLC increased its position in TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after purchasing an additional 62,542 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in TriSalus Life Sciences during the third quarter valued at $92,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.